Biotech Stock Dyne Adds To 108% Run As It Takes On Sarepta's Exondys 51

Top-notch biotech stock Dyne broke out Monday after the company unveiled promising test results for a pair of muscular dystrophy drugs.

Related Keywords

Sarepta Exondys , ,Dyne Therapeutics ,Sarepta Therapeutic ,Relative Strength Rating ,